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To investigate the biological processes that are
altered in obese subjects, we generated cell-specific
integrated networks (INs) by merging genome-scale
metabolic, transcriptional regulatory and protein-pro-
tein interaction networks. We performed genome-
wide transcriptomics analysis to determine the global
gene expression changes in the liver and three adi-
pose tissues from obese subjects undergoing bariat-
ric surgery and integrated these data into the cell-
specific INs. We found dysregulations in mannose
metabolism in obese subjects and validated our pre-
dictions by detectingmannose levels in the plasma of
the lean and obese subjects. We observed significant
correlations between plasma mannose levels, BMI,
and insulin resistance (IR). We also measured plasma
mannose levels of the subjects in two additional
different cohorts and observed that an increased
plasmamannose level was associated with IR and in-
sulin secretion. We finally identified mannose as one
of the best plasma metabolites in explaining the vari-
ance in obesity-independent IR.
INTRODUCTION
Obesity is associated with an increased risk for a wide range of
morbidities, including insulin resistance (IR), type 2 diabetes
(T2D), non-alcoholic fatty liver disease (NAFLD), and cardiovas-
cular disease (CVD). Although the prevalence of obesity con-
tinues to dramatically increase worldwide, a clear understanding172 Cell Metabolism 24, 172–184, July 12, 2016 ª 2016 Elsevier Inc.of the underlyingmolecular mechanisms involved in the progres-
sion of associated disorders is still lacking. Several attempts
have been made to reveal the metabolic processes that are
altered in obesity (Mardinoglu et al., 2013, 2015a, 2014b),
NAFLD (Hyötyläinen et al., 2016; Mardinoglu et al., 2014a), and
T2D (Väremo et al., 2015) through the use of genome-scale
metabolic models (GEMs). GEMs are collections of biochemical
reactions and their catalyzing protein-coding genes and they
have been widely used in the identification of biomarkers as
well as drug targets for the development of effective treatment
strategies for metabolism-related disorders (Björnson et al.,
2015; Bordbar et al., 2014; Mardinoglu and Nielsen, 2012,
2015; Mardinoglu et al., 2015b; O’Brien et al., 2015; Shoaie
et al., 2015; Uhlén et al., 2016; Yizhak et al., 2013, 2014a,
2014b; Zhang et al., 2015).
Metabolism is precisely regulated in response to internal and
external stimuli, and the expression of metabolic enzymes is
uniquely controlled by transcriptional regulation in each cell/tis-
sue. Hence, it is necessary to integrateGEMswith transcriptional
regulatory networks (TRNs) that control the transcription state of
the genome to increase their predictive ability. TRNs include in-
formation on the interactions between transcription factors (TFs)
and provide insights into network hubs, hierarchical organiza-
tion, and network motifs. The architecture of TRNs derived
from ENCODE data was studied by determining the genomic
binding information of 119 TFs (Gerstein et al., 2012). Moreover,
an additional TRN that includes the associations between 475
sequence-specific TFs has been presented and its dynamic
properties have been studied in different cell/tissue types
(Neph et al., 2012b). The robustness of the gene expression phe-
notypes of these highly cell- and tissue-specific TRNs has been
extensively studied (Pechenick et al., 2014), and the integration
of TRNs and GEMs may lead to improved reconstructions of hu-
man metabolism and its regulation.
Interactions between proteins are central to all biological func-
tions, and protein-protein interaction networks (PPINs) provide
further insights into the functional organization of individual pro-
teins because proteins rarely act alone (Li et al., 2015). PPINs
have been widely used to identify potential drug targets and
study the effects of already known targets through the mapping
of protein expression data (Snider et al., 2015). Consistent PPINs
are currently available, and these networks are presented in a
number of databases constructed using community standards
(De Las Rivas and Fontanillo, 2010; Orchard et al., 2012; Szklarc-
zyk et al., 2015). The size of the PPINs continues to increase sub-
stantially with the development of high-throughput experimental
technologies, manual evaluations of relevant literature and pre-
dictions using computational methods (Szklarczyk et al., 2015).
Recently, Rolland et al. (2014) presented a systematic map of
14,000 human binary protein-protein interactions, and this
high-quality reference PPIN was used to generate the cell-spe-
cific PPINs used in our study.
While GEMs, TRNs, and PPINs can each provide new insights
as to the metabolic processes that become dysfunctional in
obesity, the integration of these networks can likely provide a
more complete and multifaceted understanding of these
biological processes. Such integration has not previously
been attempted. Here, we integrated functional GEMs for
hepatocytes (iHepatocytes2322) (Mardinoglu et al., 2014a), my-
ocytes (iMyocytes2419) (Väremo et al., 2015), and adipocytes
(iAdipocytes1850) (Mardinoglu et al., 2013, 2014b) with TRNs
and PPINs to generate cell-specific integrated networks (INs).
We employed these INs to explore the biological processes
that are altered in obesity in the context of whole-body functions
(Figure 1A).
RESULTS
Human Cell-Specific Regulatory Networks
The generation of INs by integrating TRNs, PPINs, and GEMs is
necessary for a more comprehensive understanding of the
mechanisms involved in the progression of chronic diseases.
To generate human cell-specific TRNs, we retrieved DNase
sequencing (DNase-seq) data from metabolically active cell
types, including hepatocytes, myocytes, and adipocytes, from
the ENCODE repository (ENCODE Project Consortium, 2012)
(Table S1). DNase-seq identifies regions of open (and hence
actively regulated) chromatin based on accessibility by the
DNase I endonuclease (Crawford et al., 2006). We also retrieved
DNase-seq data from hepatic stellate cells, skeletal myoblasts,
and myotubes to evaluate our cell-specific TRNs from hepato-
cytes and myocytes. We first checked the quality of the
DNase-seq samples and analyzed the DNase-seq data following
the pipeline introduced by the ENCODE consortium (Neph et al.,
2012c) (Figure S1A).
We compared the footprint occupancy scores (FOS) of poten-
tial TF-binding sites among the samples in a pairwise manner
and found that the samples with the same tissue of origin had
overall higher correlations (Figure 1B). After generating cell-spe-
cific reference TRNs for hepatocytes, myocytes, and adipocytes
(Figure S1; Table S1), we compared the contents of the TRNs
(Figure 1C) and observed that the interactions between the TFs
and target genes were specific to the cell type. Higher overlapwas observed between the TRNs for adipocytes and myocytes
compared to their overlaps with the TRNs for hepatocytes (Fig-
ures S1B and S1C). We also found that the TRNs of hepatocytes
and myocytes had higher similarities with the TRNs of the adja-
cent cells, including hepatic stellate cells and skeletal myoblasts
and myotubes (Figures S1D–S1F).
To evaluate the cell-specific TRNs for hepatocytes, myocytes,
and adipocytes, we compared the regulatory interactions of TFs
with the interactions in previously presented TRNs generated
based on ENCODE ChIP-seq data (Gerstein et al., 2012) and
published literature in the Pathway Commons database (Cerami
et al., 2011). We only compared the interactions among 64 TFs
that were consistently present in all three sources and compared
their corresponding regulatory interactions (Figure 1D). We
compared the regulatory interactions in our TRNs with the inter-
actions in the TRNs generated based on ENCODE ChIP-seq
data and found that 53.9% of the interactions in our TRNs (Jac-
card index [JI]: 0.125) were shared between these two networks.
We also compared the TRNs generated herein as well as the
TRNs generated based on ENCODE chromatin immunoprecipi-
tation sequencing (ChIP-seq) data with the TRNs retrieved from
the Pathway Commons database and found minor similarities
among these networks (JI: 0.0301 and JI: 0.0290, respectively).
The relatively low coverage of cell-specific regulatory interac-
tions in the knowledge-based databases illustrates the impor-
tance of generating cell-specific TRNs based on DNase-seq
and ChIP-seq data.
Refinement of Cell-Specific Networks Using Proteomic
and Transcriptomic Data
DNase-seq data can be used to identify the binding regions of
TFs; however, all of the regulatory interactions in the reference
TRNsmay not be observed in the biological samples. To remove
false-positive regulatory interactions from the reference TRNs,
we refined our cell-specific TRNs using cell-specific antibody-
based proteomic data from hepatocytes, myocytes, and adipo-
cytes as well as tissue-specific RNA-seq data from liver, muscle,
and adipose tissues obtained from healthy subjects in the Hu-
man Protein Atlas (HPA) (ver.14) (Uhlén et al., 2015) (Figure S2A).
The presence or absence of 17,005 unique proteins in each cell
type was evaluated using 25,039 antibodies, and the abundance
or absence of the proteins was evaluated as ‘‘high,’’ ‘‘medium,’’
‘‘low,’’ or ‘‘not detected.’’
We removed the TFs and target genes from the cell-specific
TRNs if there was negative evidence (Not detected) for the
presence of the protein in the cell type and lower mRNA abun-
dance (fragments per kilobase of exon per million fragments
mapped [FPKM] <1) in the corresponding tissues (Table S2).
We compared the overlap of the target genes in the TRNs with
the metabolism-related (metabolic) genes in the GEMs and
found that more than 26% of the metabolic genes were present
in the TRNs for each cell type (Figure 2A). Moreover, we analyzed
the topological characteristics of the TRNs by examining the
out-degrees of TFs and the in-degrees of target genes and
comparing their degrees across the cell types (Figures S2C–
S2H) and observed that while the out-degrees of the TFs re-
mained relatively stable across cell types, the in-degrees of
target genes revealed that TFs were binding to different sets of
target genes in each cell type.Cell Metabolism 24, 172–184, July 12, 2016 173
Figure 1. Generation of Cell-Specific Regulatory Networks
(A) To create integrated networks (INs) for hepatocytes, myocytes, and adipocytes, we generated cell-specific regulatory networks (RNs) using DNase-seq data
and integrated these networks with cell-specific protein-protein interaction networks (PPINs) and genome-scalemetabolicmodels (GEMs).We refined the INs for
the healthy subjects based on the cell-specific antibody-based proteomic data and tissue-specific transcriptomic data in the Human Protein Atlas. We also
generated RNA sequencing data from liver tissue and three different adipose tissues of the obese subjects and used these data in the generation of the INs for the
obese subjects. We performed a comparative analysis between the INs of the lean and obese subjects and identified metabolic pathways with decreased or
increased co-regulation. Finally, we validated our network-based predictions in three different independent cohorts with varying BMI values, insulin resistance,
and insulin secretion values.
(B) We compared replicates of the DNase-seq samples based on their footprint occupancy scores (FOS) in a pairwise manner and found high correlations
between the cell-type replicates.
(C) After selecting potential TF-binding sites with high FOS scores over all of the replicates of a given cell type, we generated cell-specific TRNs based on the
irreproducible discovery rate (IDR). We compared the TFs, target genes and interactions in each cell-specific TRN.
(D) We evaluated our cell-specific TRNs with other TRNs generated based on ENCODE ChIP-seq data and manually curated knowledge from the literature in the
PathwayCommons database.We compared the corresponding regulatory interactions of 64 TFs that were consistently present in all three TRNswith other target
genes. We found that our TRN had a high overlap with the ENCODE ChIP-seq data (53.9%).
See also Figures S1 and S7, Tables S1–S3, and Data S1.We obtained a recently published generic human PPIN (Roll-
and et al., 2014) and refined this reference network using cell-
specific antibody-based proteomic data and tissue-specific
RNA-seq data in HPA (Uhlén et al., 2015). We generated cell-
specific PPINs for healthy hepatocytes, myocytes, and adipo-
cytes by removing genes without protein abundance (‘‘Not
detected’’ in the corresponding cell) or low mRNA abundance
(FPKM <1) in the corresponding tissue (Table S2).
We compared the protein-coding genes in the resulting cell-
specific PPINs and GEMs and found that 381 genes were shared174 Cell Metabolism 24, 172–184, July 12, 2016between the PPIN for hepatocytes and iHepatocytes2322, 408
genes were shared between the PPIN for myocytes and
iMyocytes2419, and 322 genes were shared between the PPIN
for adipocytes and iAdipocytes1850 (Figure 2B). Although
there was relatively good overlap between the genes in the cell-
specific PPINs and the TFs and target genes in the cell-specific
TRNs (Figure 2C), we detected almost no overlap between the in-
teractions in these networks (Figure 2D), which suggests that
PPINs and TRNs should be integrated with GEMs to elucidate








Figure 2. Generation of Cell-Specific Integrated Networks
(A) We investigated the overlap between the target genes of cell-specific regulatory networks (RNs) and metabolic genes in their corresponding cell-specific
genome-scale metabolic models (GEMs) for hepatocytes (iHepatocytes2322), myocytes (iMyocytes2419), and adipocytes (iAdipocytes1850).
(B) Similarly, we examined the overlap between the protein-coding genes in the cell-specific protein-protein interaction networks (PPINs) with the metabolic
genes in the corresponding cell-specific GEMs.
(C) A comparison of the protein-coding genes in the cell-specific PPINs with TFs and target genes in the cell-specific TRNs showed relatively good overlap
between the genes.
(D) However, when we examined the overlap of interactions between the cell-specific TRNs and PPINs, we found almost no overlap between these networks.
(E) After integrating the cell-specific TRNs and PPINs, we examined the overlap between the protein-coding genes with the metabolic genes in the GEMs and
found relatively higher overlap between them.
(F) We analyzed the co-regulation of all enzymes in the cell-specific integrated networks (INs) by establishing a weighted edge betweenmetabolic genes that had
co-regulating TFs and/or proteins.
(G)We identified highly co-regulatedmetabolic pathways from a co-regulation analysis performed using themetabolic genes involved in eachmetabolic pathway
by a Bonferroni-adjusted Kolmogorov-Smirnov one-sided test. Fructose and mannose metabolism, glycerophospholipid metabolism, and cholesterol biosyn-
thesis were highly co-regulated in the hepatocytes; fructose and mannose metabolism, leukotriene metabolism, and glycolysis were highly co-regulated in the
myocytes; and fructose and mannose metabolism, propionate metabolism, and glycolysis were highly co-regulated in the adipocytes.
See also Figures S2–S4, Table S4, and Data S1.Highly Co-regulated Metabolic Pathways in Healthy
Subjects
We first integrated the TRNs and PPINs for hepatocytes, myo-
cytes, and adipocytes (Table S2) and found that 37.3%
of the genes in iHepatocytes2322, 58.2% of the genes in
iMyocytes2419, and 38.4% of the genes in iAdipocytes1850
were regulated by TFs or other target genes in the TRNs and
PPINs (Figure 2E). To gain further insights into the metabolism
of cells and tissues, we generated cell-specific INs for
hepatocytes, myocytes, and adipocytes by integrating the cell-specific GEMs, TRNs, and PPINs (Table S2). We examined the
degree to which each metabolic pathway in a cell-specific GEM
was concurrently regulated by TFs and targets in the TRNs and
PPINs by analyzing the co-regulated functions (Figure 2F). We es-
tablished a weighted edge between the metabolic genes that we
call the co-regulation strength (counting the number of co-regu-
lating TFs and proteins asweight) and examined the co-regulation
strengths of the metabolic pathways of each cell type.
We identified the highly co-regulated metabolic pathways in
each cell type based on the co-regulation strengths and thenCell Metabolism 24, 172–184, July 12, 2016 175
Table 1. Clinical Characteristics of the 12 Obese Subjects
Undergoing Bariatric Surgery
Clinical Variable Obese Subjects
Number of subjects 12
Age (years) 39.3 ± 10.9
Weight (kg) 122.9 ± 12.8
BMI (kg/m2) 43.6 ± 3.6
Fasting plasma glucose (mmol/l) 5.6 ± 0.6
Fasting plasma insulin (FPI) (pmol/l) 128.7 ± 49.9
HOMA-IR 4.7 ± 1.9
Plasma triglycerides (TG) (mmol/l) 1.5 ± 0.5
Total cholesterol (mmol/l) 5.1 ± 0.7
LDL cholesterol (mmol/l) 3.1 ± 0.7
HDL cholesterol (mmol/l) 1.3 ± 0.3
Alanine aminotransferase (ALT) (U/l) 25.3 ± 16.3
g-Glutamyl transferase (mGT) (U/l) 30.7 ± 23.2
The data are presented as the mean ± SD.examined the global characteristics of the co-regulation strengths
of all gene pairs in the INs (Figure S3) and tested each metabolic
pathway to see if its co-regulation strength was greater than or
less than the overall co-regulation of the INs (Figure 2G; Data
S1A) (see the Experimental Procedures). For each cell type, we
found different sets of highly co-regulated pathways (adjusted p
value < 0.05). During the co-regulation analysis, we used the
metabolic genes involved in a specific pathway and their sur-
rounding TFs or proteins in the cell-specific INs. We found that
fructose and mannose metabolism, glycerophospholipid meta-
bolism, and cholesterol biosynthesis were highly co-regulated in
hepatocytes; fructose and mannose metabolism, glycolysis,
and leukotriene metabolism were highly co-regulated in myo-
cytes; and fructose and mannose metabolism, glycolysis, and
propionate metabolism were highly co-regulated in adipocytes.
These top co-regulated metabolic pathways are highly rele-
vant for tissue-specific functions. For example, glycerophospho-
lipid metabolism and cholesterol biosynthesis, which were found
to be significantly and specifically co-regulated in hepatocytes,
are known to be regulated by the liver through lipoprotein secre-
tion (Tijburg et al., 1989). Similarly, leukotriene metabolism and
glycolysis, which were found to be significantly and specifically
co-regulated in myocytes, are known to play a major role in
triggering and fueling muscle contractions (Balsom et al., 1995;
Setoguchi et al., 2001). Moreover, propionatemetabolism, which
was found to be significantly and specifically co-regulated in
adipocytes, is known to control the lipid-buffering capacity of
adipose tissue (Canfora et al., 2015). These findings strongly
suggest that co-regulation strength is a good indicator of tis-
sue-specific metabolism regulation.
Dysregulation of Fructose and Mannose Metabolism in
Obese Subjects
After generating the detailed INs for healthy subjects, we next
sought to determine how INs differed in obesity. To generate
obese-specific INs, we obtained liver samples and three
different adipose tissue depots, including subcutaneous,
omental, and mesenteric, from 12 morbidly obese (BMI >40)176 Cell Metabolism 24, 172–184, July 12, 2016subjects undergoing bariatric surgery. We then performed global
gene expression profile analyses using RNA sequencing. The
clinical characteristics of all of the subjects involved in our study
are presented in Table 1.
As we did previously for the healthy subjects, we generated
cell-specific TRNs and PPINs for the obese subjects by refining
the reference networks using the mRNA expression levels of the
genes in the liver and adipose tissue samples. Genes with low
mRNA expression (FPKM <1) were excluded from the reference
networks for the hepatocytes and adipocytes (Table S2). During
the generation of adipocyte-specific networks for the obese
subjects, we accounted for differences in the three adipose tis-
sue depots, including subcutaneous, mesenteric, and omental
fat (Figure S4A) and excluded genes from the reference networks
only if the RNA expression level of the genes was low (FPKM <1)
in all three adipose tissue samples in all of the obese subjects
(Table S2).
We performed a co-regulation analysis for each metabolic
pathway in the healthy and obese subjects based on the network
topology provided by the cell-specific INs. Next, we compared
their co-regulation strengths in the hepatocytes (Figure 3A) and
adipocytes (Figure 3B) based on the number of co-regulators
and identified the metabolic pathways for which co-regulation
decreased or increased. We found that the co-regulation of fruc-
tose andmannosemetabolismwas significantly decreased (Kol-
mogorov-Smirnov [KS] one-sided test, p < 0.05) in the hepato-
cytes of the obese subjects (Figure 3A; Data S1B), whereas the
co-regulation of propionate metabolism was slightly increased
in the adipocytes of the obese subjects (Figure 3B; Data S1C).
Moreover, we compared the mRNA expression levels of the
protein-coding genes from the human liver and subcutaneous
adipose tissue samples obtained from 12 obese subjects (Table
1) with seven liver and five subcutaneous adipose tissue samples
obtained from the healthy subjects (previously described in Uh-
lén et al., 2015). We first clustered the biological samples using
the mRNA expression level of the protein-coding genes and
found that the liver samples from the obese and healthy subjects
as well as the adipose tissue samples from the obese and
healthy subjects clustered together (Figure S4B). We identified
differentially expressed genes (adjusted p value < 0.05) to reveal
the global biological differences between the liver and subcu-
taneous adipose tissue of the obese and healthy subjects, and
the results indicated that 6,496 genes in the liver tissue (Data
S1D) and 1,298 genes in the subcutaneous adipose tissue
(Data S1E) were differentially expressed. To gain greater insight
into the biological processes altered in the liver and adipose tis-
sue of the obese subjects relative to the healthy individuals, we
performed a gene set analysis (GSA) for gene ontology (GO) bio-
logical process (BP) terms. We found that the gene sets that
included the terms regulation of cellular metabolic process,
post translational protein modification, negative regulation of
biological process and immune response were associated with
downregulated genes, whereas the metabolism-related BP
terms, including lipidmetabolic process, phospholipidmetabolic
process, phosphoinositide metabolic process, and fatty acid
b-oxidation, were associated with upregulated genes in the liver
tissue of the obese subjects (Figure S5). We also found that the
gene sets that included the terms regulation of RNA metabolic
process, regulation of cell proliferation, and positive regulation
Figure 3. Revealing Biological Processes Altered between Healthy and Obese Subjects
We refined the reference cell-specific networks using transcriptomic data from the obese subjects and compared the co-regulations of the metabolic pathways
between the (A) hepatocytes and (B) adipocytes of the healthy and obese subjects. We also compared the number of regulated enzymes in the INs of hepatocytes
and adipocytes from the healthy and obese subjects and did not observe significant differences. Among the significantly co-regulated metabolic pathways
(Kolmogorov-Smirnov [KS] test, Bonferroni-adjusted p value < 0.05) in Figure 2G, we examined the changes in co-regulation strength between the healthy and
obese subjects based on the number of co-regulators. We found that the highly co-regulated metabolism of fructose and mannose presented substantially
decreased co-regulation in the hepatocytes (KS one-sided test p < 0.05), whereas propionate metabolism presented weakly increased co-regulation in the
adipocytes. Reporter metabolites were identified in the (C) liver and (D) adipose tissues of the lean and obese subjects. Detailed metabolic differences between
the lean and obese subjects were investigated through a comparative analysis of the gene expression profiles (RNA-seq) of the liver and adipose tissues and cell-
specific genome-scale metabolic models (GEMs). P values for each reporter metabolite were calculated for the upregulated and downregulated genes.
See also Figures S5 and S6 and Data S1.
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of biological process were associated with downregulated
genes, whereas metabolism-related BP terms including carbox-
ylic acid metabolic process and lipid metabolic process were
associated with upregulated genes in the subcutaneous adipose
tissue of the obese subjects (Figure S6). Taken together, our data
indicated an increased activity in lipid metabolism in both the
liver and fat in obese subjects as well as novel differences in
pathways such as the immune response and RNA metabolism.
To evaluate the detailed metabolic differences between the
lean and obese subjects, we identified reporter metabolites (Patil
and Nielsen, 2005) using the differentially expressed genes in the
liver and adipose tissue aswell as the network topology provided
by the cell-specific GEMs. Reporter metabolite analyses are
used as statistical tests to determine whether a significant
change has occurred in the expression of the genes surrounding
a metabolite. We identified mannose, mannose-1-phosphate,
mannose-6-phosphate, GDP-mannose involved in fructose,
and mannose metabolism as well as other metabolites involved
in inositol phosphate, glycerophospholipid, and vitamin E meta-
bolism as reporter metabolites in the liver tissue (Figure 3C; Data
S1F). We also identified the metabolites involved in leukotriene,
vitamin E, and lipid metabolism as reporter metabolites in adi-
pose tissue (Figure 3D; Data S1G).
Plasma Mannose Levels Are Increased in Response to
Obesity
We observed that the co-regulation of the highly co-regulated
metabolism of fructose and mannose was significantly
decreased in the liver of the obese subjects compared with
that of the lean subjects. Moreover, mannose, an essential hex-
ose that is required for glycoprotein synthesis (Davis and Freeze,
2001), as well as other associated metabolites were identified as
top-ranked reporter metabolites in the liver tissue of the obese
subjects. We examined the expression of genes associated
with the utilization of mannose and found significant (adjusted
p value < 0.05) differences in the expression of these genes in
the liver tissue of the obese subjects compared with that of the
lean subjects (Figure 4A). The expression levels of HK1 and
HK2, which convert mannose to mannose-6-phosphate, were
significantly downregulated in the liver tissue of the obese sub-
jects (Figure 4B). However, we found that the expression of en-
zymes involved in the metabolism of glucose into fructose and
mannose (e.g., PMM1) was significantly upregulated. Notably,
when we analyzed the co-regulations among these enzymes,
we found that PMM1, PFKL, GMPPB, and GMPPA were highly
co-regulated (Figure 4C) and the expression levels of these reg-
ulators were significantly changed (Figure 4D). Hence, we
observed that there was a shift in the utilization of carbohydrates
in the liver tissue of the obese subjects. Because the liver is one
of the main organs responsible for plasma mannose consump-
tion (Davis and Freeze, 2001), we hypothesized that due to the
downregulation of genes responsible for mannose processing
in the liver, the levels of mannose in the plasma would be
increased.
To evaluate our hypothesis, we detected the plasma levels of
mannose, glucose, and fructose in 399 subjects involved in the
Relationship between Insulin Sensitivity and Cardiovascular
Disease (RISC) Study (Balkau et al., 2008; Hills et al., 2004).
The RISC Study is being conducted in 19 European recruiting178 Cell Metabolism 24, 172–184, July 12, 2016centers, and the insulin sensitivity (IS) of each subject is
measured with the euglycemic clamp technique. The clinical
characteristics of all of the lean, overweight, and obese subjects
involved in the study are presented in Table 2. We measured the
plasma mannose, fructose, and glucose levels in these subjects
by liquid chromatography-mass spectrometry and found that
the mannose and glucose plasma levels were significantly
(p value < 0.05) higher in the obese subjects compared with
the lean subjects, whereas significant changes were not
observed in the fructose plasma levels (Figure 5A).
Moreover, we calculated Spearman’s correlation coefficient (r)
between the BMI and plasma mannose levels as well as the
glucose levels in 399 subjects and found that the BMI was signif-
icantly correlated with the plasma mannose levels (r = 0.43,
p value < 0.05) and plasma glucose levels (r = 0.28, p
value < 0.05), whereas significant correlations were not observed
with the plasma fructose levels (Figure 5B). Considering
the negative correlation between the BMI and IS (r = 0.42,
p value < 0.05) (Figure 5B), we also examined the correlations
between IS and the plasma mannose and glucose levels. Our
correlation analysis indicated that slightly lower negative correla-
tions occurred between the IS and themannose levels (r=0.19,
p value < 0.05) relative to the IS and the glucose levels (r =0.15,
p value < 0.05) (Figure 5B).
Moreover, we found significantly high correlations between
glucose and mannose (r = 0.64, p value < 0.05). To eliminate
the effect of glucose, we performed partial correlation analysis,
which can control confounding variables’ effect (i.e., glucose)
removed within ordinary correlation analysis. Partial correlation
analysis showed that mannose was significantly correlated
with both BMI (r= 0.34, p value < 0.05) and IS (r=0.13, p value <
0.05) without the effect of glucose in the RISC study (399 lean
and obese subjects). In contrast, we found that glucose is not
significantly correlated with BMI and IS after eliminating the ef-
fect of mannose (p values = 0.83 and 0.44, respectively).
Plasma Mannose Levels Are Associated with Insulin
Resistance
We observed a significantly positive correlation between the
plasmamannose levels and BMI and a significantly negative cor-
relation between the plasmamannose levels and IS. To reveal the
distinct association between the plasma mannose levels and IS
without the effect of BMI, we recruited an additional 79 male
and female obese patients involved in the Leipzig study (Klöting
et al., 2010). The IS of each subject involved in the study was
measured with the euglycemic clamp technique, and the clinical
characteristics of all of the obese subjects involved in the study
are presented in Table 2. We separated the obese subjects into
two groups based on their IS using previously described criteria
(Klöting et al., 2010) and then measured their plasma glucose,
mannose, and fructose levels. We found that plasma mannose
and glucose levels were significantly higher in the IR obese sub-
jects compared with the IS obese subjects, whereas we did not
detect significant differences in the plasma fructose levels be-
tween the two groups of obese subjects (Figure 5C).
We calculated the correlations between the IS and plasma
mannose, fructose, and glucose levels. We observed that the
IS was negatively correlated with the plasma mannose level
(r = 0.28, p value < 0.05), whereas significant correlations
Figure 4. Substrate Shifts in the Liver Tissue of the Obese Subjects
(A) We identified ametabolic pathway for the utilization of mannose and glucose in the liver tissue. Upregulated and downregulated enzymes and reactions in the
obese subjects are represented as red and blue, respectively. The changed reactions implied that the consumption of mannose was decreased and the utilization
of carbohydrates was altered (A).
(B) Fold changes of the corresponding enzyme expression levels.
(C and D) We found that the enzymes involved in mannose and glucose utilization were highly co-regulated with each other, and their regulators (TFs or proteins
physically interacting with them [green rectangle]) were differentially expressed. Non-expressing regulators (FPKM <1) in the obese subjects or healthy subjects
were identified as a maximal fold change of 10 or 10, respectively.were not observed between the IS and plasma glucose and fruc-
tose levels in the obese subjects (Figure 5D). After eliminating the
effect of glucose, we found that mannose is significantly corre-
lated with IS (r = 0.20, p value < 0.05), whereas glucose is
not significantly correlated with IS after eliminating the effect of
mannose (p value = 0.95). Hence, we observed that the plasma
mannose levels could be used to identify obese subjects with
high risk factors.
Plasma Mannose Levels Are Associated with Insulin
Secretion
We also detected the plasma levels of mannose, glucose, and
fructose in another independent cohort of 80 male and female
subjects involved in the population-based EUGENE2/Kuopio
Study, where the phenotype of individuals with impaired fasting
glucose and/or impaired glucose tolerance with regard to insulinsecretion and IR was examined (Laakso et al., 2008). Evaluations
of insulin secretion (InsAUC0-30/GlucAUC0-30) and IS have
been previously described (Matsuda and DeFronzo, 1999;
Stancáková et al., 2009). The subjects presented varying dispo-
sition indices (DIs), which were calculated as the product of the
indices of IS and insulin secretion (InsAUC0-30/GlucAUC0-30).
The characteristics of the study participants are presented in
Table 2.
We classified the patients as low or high DI and found that the
plasma glucose and mannose levels were significantly higher in
the subjects with low DI relative to the subjects with high DI. Sig-
nificant changes were not observed in the plasma fructose levels
(Figure 5E). Moreover, we calculated the correlations (r) between
the BMI, IS, DI, and plasma mannose, glucose, and fructose
levels and found that the plasmamannose level was significantly



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































180 Cell Metabolism 24, 172–184, July 12, 2016p value < 0.05) (Figure 5F). In addition, significant correlations
were not observed between the DI or IS and glucose or fructose
in this subject group. We finally observed that mannose is signif-
icantly correlated with BMI (r = 0.34, p value < 0.05) and IS (r =
0.25, p value < 0.05) after eliminating the effect of glucose
whereas glucose is not significantly correlated with BMI or IS af-
ter eliminating the effect of mannose (p values = 0.89 and 0.72,
respectively).
The Use of Plasma Mannose Level in Explaining the
Variance in IR
We performed relative importance analysis (Lindeman et al.,
1980) to estimate how much various plasma metabolite levels
contributed in explaining the variance in IR (as measured with
the euglycemic clamp technique). During the analysis, we
included the plasma measurements of mannose, glucose, fruc-
tose, and 20 amino acids (available in the datasets) as well as
a-hydroxybutyrate (AHB). The plasma levels of some amino
acids, including branched-chain amino acids, leucine, isoleu-
cine, and valine, have already been associated with IR (Newgard
et al., 2009). AHB has also been proposed as an early biomarker
of IR and glucose intolerance in a nondiabetic subjects (Gall
et al., 2010). The contributions of the metabolites were summed
up to 100 and divided up per metabolite so that the relative
contribution to explain the variance in IR (as percentage of the to-
tal explained variance) is displayed in lean and obese subjects
(Figure 5G) in obese subjects with IR and IS (Figure 5H) and in
subjects with varying DIs andmatched BMI (Figure 5I). We found
that mannose is the best metabolite whose plasma level can be
used in explaining the variance of IR in subject groups with
matched BMI (Figures 5H and 5I).
Plasma levels of mannose, glucose, and other metabolites al-
lowed us to compare not only mannose and glucose levels, but
also the level other potential markers of IR. Considering that
plasma mannose levels outperformed the level of metabolites
that have been associated with IR, we suggested to use of
plasma mannose levels in stratification of the obese subjects
with high risk factors independent of BMI.
DISCUSSION
Recent advances in sequencing technologies and methods for
genomic analyses (e.g., digital genomic foot printing) have al-
lowed for the massive profiling of in vivo regulatory events in
human cells and tissues. In our study, we examined the regu-
latory events in hepatocytes, myocytes, and adipocytes and
generated cell-specific TRNs. We integrated the TRNs with
GEMs and PPINs and eventually generated cell-specific INs
to investigate the biological processes that are altered in the
patients presenting obesity and IR based on the network
topology provided by the networks. We refined the topology
of the cell-specific INs using the cell-specific antibody
proteomic and tissue-specific transcriptomic data in the HPA
(Uhlén et al., 2015). Moreover, we generated RNA-seq data
from the liver samples and three different adipose tissue de-
pots obtained from the obese subjects and used these
data in the generation of INs for the obese subjects. We
performed a comparative analysis between the lean and






Figure 5. Detection of Plasma Mannose Levels in Obese Subjects
(A) We detected the plasma glucose, mannose, and fructose levels in the lean and obese subjects and found that glucose, mannose levels were significantly
upregulated in the obese subjects compared with the lean subjects.
(B) We observed significant correlations between the BMI and the plasma mannose levels as well as the plasma glucose levels. We also calculated the cor-
relations between insulin resistance (IR) and the plasma mannose levels as well as the plasma glucose levels and found significantly higher correlations between
IR and the plasma mannose levels.
(C) We detected the plasma glucose, mannose, and fructose levels in the obese subjects with and without insulin resistance (IR). We found that the plasma
glucose and mannose levels were significantly upregulated in the obese subjects with IR compared with the obese subjects with insulin sensitivity (IS).
(D) We observed significantly higher correlations between IR and the plasma mannose levels relative to the correlations between IR and the plasma glucose
levels.
(E) We detected the plasma glucose, mannose, and fructose levels in the subjects with varying disposition indices (DIs). We found that the plasma glucose and
mannose levels were significantly upregulated in the subjects with low DIs compared with the subjects with high DIs.
(F) We observed significantly correlations between IS and DIs and the plasma mannose levels and did not observe correlations between the DI or IS and glucose
or fructose in this subject group.
(G–I) The results of the relative importance analysis that has been performed to estimate howmuch various plasmametabolite levels contributed in explaining the
variance in IS. Plasmameasurements ofmannose; glucose, fructose, and 20 amino acids (available in the datasets) as well as a-hydroxybutyrate (AHB) were used
in the analysis and the importance of mannose in (G) lean and obese subjects (H) obese subjects with IR and IS (I) in subjects with varying DIs was presented.altered in response to obesity and validated our predictions by
performing a metabolomic analysis in three independent co-
horts of subjects.The power of the IN strategy allowed us to take a more com-
plete look at the role metabolism plays in obesity across multiple
tissues. We compared the cell-specific INs between lean andCell Metabolism 24, 172–184, July 12, 2016 181
obese subjects and investigated the biological differences in
response to obesity. The integration of complex biological net-
works enables the elucidation of metabolic adaptations as well
as other hallmarks of IR. We found that the co-regulation of fruc-
tose andmannosemetabolismwas decreased in the obese sub-
jects, and metabolites involved in fructose and mannose meta-
bolism were identified as a reporter metabolite. This finding
implies that mannose may be used as a marker in identification
of obese subjects with high risk factors, e.g., insulin resistance
and secretion. We also found a significant downregulation of
mannose phosphorylation (HK1 and HK2) in the liver tissue,
which may lead to decreased plasma mannose utilization in
the liver tissue. The downregulation of HK1 and HK2 might
also lead to decreased glucose utilization. However, this
decrease could be compensated for by the upregulation of
glucose-specific phosphorylase GCK in obese patients. GCK
is an enzyme with a relatively high half-saturated concentration
(KM) (GCK = 10 mM) compared with other hexokinases
(0.1 mM) (Ahn et al., 2009; Magnani et al., 1988; Xu et al.,
1995). Thus, the utilization of glucose in the liver tissue was not
decreased in the obese patients as previously reported (Caro
et al., 1984). This finding can help explain why mannose had bet-
ter correlation with IR than glucose.
The liver has been reported as the main organ for mannose
consumption (Davis and Freeze, 2001). Therefore, altered
mannose utilization in the liver tissue could lead to differences
in plasma mannose levels. To validate our predictions, we first
measured the plasma mannose levels in the lean and obese
subjects and found that the plasma mannose levels were
significantly upregulated in the obese subjects. Alterations in
mannose metabolism may affect glycoprotein synthesis and
secretion since mannose is the main source of glycoprotein
synthesis (Panneerselvam et al., 1997; Panneerselvam and
Freeze, 1996). Abnormal glycosylation could also affect the in-
sulin receptors in the liver tissue and increase the resistance of
liver tissue to insulin (Caro et al., 1984). Therefore, we specu-
lated that the plasma mannose levels could potentially play a
supplementary role in the development of IR. In accordance
with this hypothesis, we found that the plasma mannose levels
were significantly negatively correlated with the IS of lean and
obese subjects. In addition, we investigated whether plasma
mannose level was significantly different between IR and IS in-
dependent of BMI and measured the plasma mannose levels
of 79 obese subjects classified into two groups based on their
IR and IS. We found that the plasma mannose levels were
significantly higher in the IR obese subjects compared with
the IS obese subjects, and this level was significantly nega-
tively correlated with the patient’s IS. We also measured the
plasma mannose levels of 80 subjects classified into two
BMI matched groups based on their DI. We found that the
plasma mannose levels were significantly higher in the sub-
jects with low DI compared with the subjects with high DI,
and this level was significantly negatively correlated with the
patient’s DI and IS. Finally, we compared the plasma mannose
levels with the levels of glucose, fructose, AHB and amino
acids in three independent cohorts of subjects and found
that mannose outperformed most other metabolites across a
variety of conditions in explaining the variance in obesity-inde-
pendent insulin resistance.182 Cell Metabolism 24, 172–184, July 12, 2016It has been previously shown that plasma mannose levels
correlate with glucose levels but that the level of mannose is un-
like glucose not different between fasting and postprandial state
(Sone et al., 2003). This observation coupled with the closer cor-
relation of mannose to IR could indicate that using plasma
mannose levels instead of glucose as a marker of IR in the clinic
could have the potential of both improving the accuracy of as-
sessing IR and being independent of meal-timing. In conclusion,
through the integration of biological networks, we revealed the
biological processes altered in response to obesity and
observed an association between plasma mannose levels and
BMI as well as insulin sensitivity and secretion. Moreover, we
demonstrated a strategy for how cell-specific INs can be em-
ployed to identify dysregulation of biological functions in
response to a disease, to reveal the consequences on relevant
metabolites in plasma and eventually to identify new candidate
disease biomarkers.
EXPERIMENTAL PROCEDURES
Identification of Genomic Footprints from DNase-Seq Data
We retrieved DNase-seq data from the hepatocytes of liver tissue (two sam-
ples), myocytes of skeletal muscle tissue (three samples), adipocytes of sub-
cutaneous adipose tissue (four samples) and stellate cells (two samples), skel-
etal myoblasts (three samples), and myotubes (two samples) from the
ENCODE repository (ENCODE Project Consortium, 2012) (Table S1). Wemap-
ped the DNase-seq data with the unaligned reads (i.e., FASTQ files) to the
reference human genome (build GRCh37/hg19) by Bowtie (ver. 1.1.1) (Lang-
mead et al., 2009) as previously described by the ENCODE Consortium
(Neph et al., 2012c) (Figure S1A). We verified the quality of the DNase-seq
samples using SPOT scores that were calculated by the HOTSPOT program
(John et al., 2011) and found that all of the samples had SPOT scores >0.4
(average 0.608 per sample) (Table S1). After counting the DNase I cleavages
per base from the mapped reads, we identified genomic footprints with their
footprint occupancy scores (FOS), and a low FOS score indicated a strong
footprint site. We found optimized footprints with a 6–40 base pair (bp) central
component and 3–10 bp flanking component. Finally, we selected footprints
within highly DNase I-sensitive regions (hotspot regions) as identified by the
HOTSPOT program (false discovery rate [FDR] <0.01) (John et al., 2011) and
selected the overlapping footprints with hotspot regions using the BEDOPS
program (Neph et al., 2012a) (see the Supplemental Experimental Procedures).
Transcript Profiling—RNA-Seq—of Liver and Adipose Tissue
Samples
Patients had low calorie diet weight reduction run in prior to the day of surgery.
The human liver and subcutaneous, omental, and mesenteric tissue samples
were obtained from 12 obese subjects undergoing bariatric surgery and
then used for the mRNA expression analyses. The tissue samples were
collected and handled in accordance with the laws and regulations of the
Netherlands as part of the sample collection. All of the human samples used
in the present study were anonymized in accordance with the approval and
advisory report from the Ethical Review Board.
A total of 48 samples from the four tissue types of the obese subjects were
sequenced using Illumina HiSeq 2000 and HiSeq 2500 systems with the stan-
dard Illumina RNA-seq protocol. The healthy samples included seven liver
samples and five adipose (subcutaneous) samples from the lean subjects (Fa-
gerberg et al., 2014; Uhlén et al., 2015), and they were compared to the 12 liver
samples and 36 adipose (12 subcutaneous, 12 mesenteric, and 12 omental)
samples from the obese subjects. Consequently, the fragments per kilobase
of exon model per million mapped reads (FPKM) values were obtained for
19,709 genes for all samples. Throughout this study, the genes with an expres-
sion level of FPKM <1 were considered to have no expression.
A differential expression (DE) analysis was performed following a standard
protocol using the differential expression sequencing (DESeq) v2.0 package
(Anders and Huber, 2010). In brief, the DE analysis was performed between
obese and lean tissue (obese liver versus lean liver and obese adipose [subcu-
taneous] versus lean adipose [subcutaneous]). In this study, expression differ-
ences with a p value < 0.05 (after Bonferroni correction) were regarded as
significantly changed.
Detection of Plasma Metabolite Levels
Measurement of plasma levels of glucose, mannose, fructose, amino acids,
and AHB was performed. Briefly, the liquid chromatography-tandem mass
spectrometry (LC-MS/MS) platform was based on a Waters ACQUITY ultra-
performance liquid chromatography (UPLC) system and a Thermo-Finnigan
LTQ mass spectrometer operated at nominal mass resolution, which was
equipped with an electrospray ionization (ESI) source and a linear ion trap
(LIT) mass analyzer.
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